文献速递肝病消化道肿瘤与早癌

肝细胞癌患者在追加治疗决策前的再分期:一项多中心队列研究

Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study.
PubMed 文献 · Hepatology · 2018-01-01

研究基于意大利两个前瞻性数据库共1196例(训练队列)和648例(验证队列)连续肝细胞癌患者,评估追加治疗前再分期的预后价值。再分期时意大利肝癌(ITA.LI.CA)评分预后表现最佳(训练队列c-index 0.707,验证队列0.722),结合进展期疾病、再分期时终末期肝病模型及非手术治疗选择构建的新模型 discriminative power 更高(c-index 0.753和0.745)。结论认为追加治疗决策时应考虑其他变量以改善预后评估。

要点

  • 再分期时35.3%患者维持稳定疾病,27.2%经治疗降期,37.5%出现疾病进展。
  • ITA.LI.CA评分在再分期时预后表现优于巴塞罗那、香港和意大利肝癌项目系统。
  • 新ITA.LI.CA再分期模型在训练和验证队列中c-index分别为0.753和0.745。

核心结论

  • 再分期时ITA.LI.CA评分预后表现最佳,但在决定肝细胞癌追加治疗时应考虑其他变量以改善预后评估。

研究设计与样本

  • 研究使用意大利两个独立前瞻性数据库,纳入2008-2015年同一研究期间接受追加治疗决策前完整再分期的连续肝细胞癌患者,训练队列1196例,验证队列648例。

主要发现

  • 再分期时35.3%患者维持稳定疾病,27.2%经治疗降期,37.5%出现疾病进展。
  • 再分期时ITA.LI.CA评分在训练队列c-index为0.707、验证队列为0.722,在所有评估系统中预后表现最佳。
  • 多变量分析显示首次治疗后疾病进展、再分期时终末期肝病模型评分及选择非手术治疗作为追加治疗可改善ITA.LI.CA评分的预后能力。
  • 新ITA.LI.CA再分期模型在训练队列c-index为0.753、验证队列为0.745。

临床怎么用

  • 作者认为,尽管ITA.LI.CA评分在再分期时预后表现最佳,但在决定肝细胞癌追加治疗时应考虑其他变量以改善预后评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Prognostic assessment of patients with hepatocellular carcinoma (HCC) at the time of diagnosis remains controversial and becomes even more complex at the time of restaging when new variables need to be considered. The aim of the current study was to evaluate the prognostic utility of restaging patients before proceeding with additional therapies for HCC. Two independent Italian prospective databases were used to identify 1,196 (training cohort) and 648 (validation cohort) consecutive patients with HCC treated over the same study period (2008-2015) who had complete restaging before decisions about additional therapies. The performance of the Italian Liver Cancer (ITA.LI.CA) prognostic score at restaging was compared with that of the Barcelona Clinic Liver Cancer, Hong Kong Liver Cancer, and Cancer of the Liver Italian Program systems. A multivariable Cox survival analysis was performed to identify baseline, restaging, or dynamic variables that were able to improve the predictive performance of the prognostic systems. At restaging, 35.3% of patients maintained stable disease; most patients were either down-staged by treatment (27.2%) or had disease progression (37.5%). The ITA.LI.CA scoring system at restaging demonstrated the best prognostic performance in both the training and validation cohorts (c-index 0.707 and 0.722, respectively) among all systems examined. On multivariable analysis, several variables improved the prognostic ability of the ITA.LI.CA score at restaging, including progressive disease after the first treatment, Model for End-Stage Liver Disease at restaging, and choice of nonsurgical treatment as additional therapy. A new ITA.LI.CA restaging model was created that demonstrated high discriminative power in both the training and validation cohorts (c-index 0.753 and 0.745, respectively). CONCLUSION: Although the ITA.LI.CA score demonstrated the best prognostic performance at restaging, other variables should be considered to improve the prognostic assessment of patients at the time of deciding additional therapies for HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Vitale A, Farinati F, Noaro G, et al. Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. Hepatology. 2018. PMID: 30048016. doi:10.1002/hep.30185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。